Author Correction: Multiplexed inhibition of immunosuppressive genes with Cas13d for combinatorial cancer immunotherapy
Tag: Cancer immunotherapy
SEED-Selection enables high-efficiency enrichment of primary T cells edited at multiple loci
Engineering T cell specificity and function at multiple loci can generate more effective cellular therapies, but current manufacturing methods prod…
Small circular RNAs as vaccines for cancer immunotherapy
Messenger RNA vaccines have shown strong prophylactic efficacy against viral infections. Here we show that antigen-encoding small circular RNAs (ci…
Microfluidic technologies for enhancing the potency, predictability and affordability of adoptive cell therapies
The development and wider adoption of adoptive cell therapies is constrained by complex and costly manufacturing processes and by inconsistent effi…
Non-viral intron knock-ins for targeted gene integration into human T cells and for T-cell selection
Current methods for the precise integration of DNA sequences into the genome of human T cells predominantly target exonic regions, which limits the…
International myeloma working group immunotherapy committee recommendation on sequencing immunotherapy for treatment of multiple myeloma
T-cell redirecting therapy (TCRT), specifically chimeric antigen receptor T-cell therapy (CAR T-cells) and bispecific T-cell engagers (TCEs) repres…
Phase 1 clinical trial of B-Cell Maturation Antigen (BCMA) NEX-T® Chimeric Antigen Receptor (CAR) T cell therapy CC-98633/BMS-986354 in participants with triple-class exposed multiple myeloma
BCMA-targeted CAR T-cells transformed the treatment of relapsed and refractory multiple myeloma (RRMM), yet improvements are needed in manufacturin…
Stabilization of EREG via STT3B-mediated N-glycosylation is critical for PDL1 upregulation and immune evasion in head and neck squamous cell carcinoma
Dysregulated Epiregulin (EREG) can activate epidermal growth factor receptor (EGFR) and promote tumor progression in head and neck squamous cell ca…